Details of the Drug Combination

General Information of Drug Combination (ID: DCIQUG5)

Drug Combination Name
ONC201 Alvespimycin hydrochloride
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs ONC201   DMM5SCF Alvespimycin hydrochloride   DM6KU93
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 4.45
Bliss Independence Score: 5.938
Loewe Additivity Score: 1.175
LHighest Single Agent (HSA) Score: 4.705

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ONC201
Disease Entry ICD 11 Status REF
Endometrial cancer 2C76 Phase 2 [2]
Glioma 2A00.0 Phase 2 [2]
Multiple myeloma 2A83 Phase 2 [2]
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Recurring respiratory infection CA07-CA45 Phase 2 [2]
leukaemia 2A60-2B33 Phase 1/2 [2]
Lymphoma 2A80-2A86 Phase 1/2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
ONC201 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [2]
Dopamine receptor (DR) TTWFZ1N NOUNIPROTAC Antagonist [4]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [2]
------------------------------------------------------------------------------------
Indication(s) of Alvespimycin hydrochloride
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [3]
Refractory hematologic malignancy 2A85.5 Phase 1 [3]
Alvespimycin hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.